Veracyte [VCYT] vs Charles River [CRL] Detailed Stock Comparison

Veracyte Inc.

NASDAQ
Loading...

Charles River Laboratories International, Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Veracyte Inc. wins in 12 metrics, Charles River Laboratories International, Inc. wins in 8 metrics, with 0 ties. Veracyte Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Veracyte Inc. Charles River Laboratories International, Inc. Better
P/E Ratio (TTM) 40.43 681.33 Veracyte Inc.
Price-to-Book Ratio 2.01 2.61 Veracyte Inc.
Debt-to-Equity Ratio 3.03 81.95 Veracyte Inc.
PEG Ratio 0.06 20.54 Veracyte Inc.
EV/EBITDA 26.79 12.23 Charles River Laboratories International, Inc.
Profit Margin (TTM) 12.83% -3.60% Veracyte Inc.
Operating Margin (TTM) 17.50% 4.51% Veracyte Inc.
EBITDA Margin (TTM) 17.50% 4.51% Veracyte Inc.
Return on Equity 5.34% -4.23% Veracyte Inc.
Return on Assets (TTM) 2.91% 4.24% Charles River Laboratories International, Inc.
Free Cash Flow (TTM) $126.63M $518.49M Charles River Laboratories International, Inc.
1-Year Return 74.15% 33.24% Veracyte Inc.
Price-to-Sales Ratio (TTM) 5.11 2.06 Charles River Laboratories International, Inc.
Enterprise Value $2.26B $10.72B Charles River Laboratories International, Inc.
EV/Revenue Ratio 4.37 2.67 Charles River Laboratories International, Inc.
Gross Profit Margin (TTM) 72.51% 31.15% Veracyte Inc.
Revenue per Share (TTM) $7 $81 Charles River Laboratories International, Inc.
Earnings per Share (Diluted) $0.82 $-2.90 Veracyte Inc.
Beta (Stock Volatility) 1.96 1.62 Charles River Laboratories International, Inc.
Short % of Float 8.87% 10.71% Veracyte Inc.

Veracyte Inc. vs Charles River Laboratories International, Inc. Stock Performance Analysis

Loading Price Chart...

VCYT
CRL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Veracyte Inc.1.88%9.46%45.59%38.83%1.99%14.89%
Charles River Laboratories International, Inc.2.91%9.35%4.38%2.38%-2.60%-11.14%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Veracyte Inc.74.15%73.43%40.68%774.34%276.75%276.75%
Charles River Laboratories International, Inc.33.24%-9.95%-46.35%110.50%383.44%347.52%

Performance & Financial Health Analysis: Veracyte Inc. vs Charles River Laboratories International, Inc.

MetricVCYTCRL
Market Information
Market Cap i$2.74B$8.28B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i744,389761,885
90 Day Avg. Volume i891,963865,618
Last Close$48.70$179.87
52 Week Range$22.61 - $50.71$132.65 - $228.88
% from 52W High-3.96%-21.41%
All-Time High$86.03 (Feb 08, 2021)$460.21 (Sep 20, 2021)
% from All-Time High-43.39%-60.92%
Growth Metrics
Quarterly Revenue Growth0.19%-0.01%
Quarterly Earnings Growth7.05%-0.01%
Financial Health
Profit Margin (TTM) i0.13%-0.04%
Operating Margin (TTM) i0.18%0.05%
Return on Equity (TTM) i0.05%-0.04%
Debt to Equity (MRQ) i3.0381.95
Cash & Liquidity
Book Value per Share (MRQ)$16.50$64.30
Cash per Share (MRQ)$5.20$4.34
Operating Cash Flow (TTM) i$136.31M$737.65M
Levered Free Cash Flow (TTM) i$86.80M$572.38M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Veracyte Inc. vs Charles River Laboratories International, Inc.

MetricVCYT (Apr 26, 2026)CRL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i40.43681.33
Forward P/E i18.8013.59
PEG Ratio i0.0620.54
Price to Sales (TTM) i5.112.06
Price to Book (MRQ) i2.012.61
Market Capitalization
Market Capitalization i$2.74B$8.28B
Enterprise Value i$2.26B$10.72B
Enterprise Value Metrics
Enterprise to Revenue i4.372.67
Enterprise to EBITDA i26.7912.23
Risk & Other Metrics
Beta i1.961.62
Book Value per Share (MRQ) i$16.50$64.30

Financial Statements Comparison: Veracyte Inc. vs Charles River Laboratories International, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVCYT (2025)CRL (2025)
Revenue/Sales i517.15M4.02B
Cost of Goods Sold i154.61M2.69B
COGS % of Revenue i29.9%67.0%
Gross Profit i362.53M1.32B
Gross Margin i70.1%33.0%
Research & Development i70.81MN/A
Operating Income (EBIT) i78.28M401.14M
Operating Margin i15.1%10.0%
EBITDA i112.86M786.81M
EBITDA Margin i21.8%19.6%
Pre-Tax Income i68.20M-99.50M
Pre-Tax Income % of Revenue i13.2%-2.5%
Income Tax i1.85M42.66M
Income Tax % of Revenue i0.4%1.1%
Net Income (Profit) i66.35M-142.16M
Profit Margin i12.8%-3.5%

Balance Sheet & Liquidity Metrics

MetricVCYT (2025)CRL (2025)
Cash & Equivalents i362.58M213.77M
Total Current Assets i488.38M1.45B
Total Current Assets % of Revenue i94.4%36.0%
Total Current Liabilities i59.94M1.12B
Total Current Liabilities % of Revenue i11.6%27.9%
Long-Term Debt i35.60M2.57B
Long-Term Debt % of Revenue i6.9%64.0%
Total Shareholders Equity i1.31B3.21B
Retained Earnings i-377.63M1.39B
Retained Earnings % of Revenue i-73.0%34.6%
Property, Plant & Equipment i73.32M361.42M

Cash Flow Statement Comparison

MetricVCYT (2025)CRL (2025)
Operating Cash Flow i111.92M194.22M
Operating Cash Flow % of Revenue i21.6%4.8%
Capital Expenditures i-9.68MN/A
Free Cash Flow i126.63M518.49M
FCF Margin i24.5%12.9%
Debt Repayment iN/A-1.35B
Common Stock Repurchase iN/A-360.67M

Short Interest & Institutional Ownership Analysis

MetricVCYTCRL
Shares Short i6.33M4.59M
Short Ratio i5.895.18
Short % of Float i8.87%10.71%
Shares Outstanding i79.36M49.22M
Float Shares i79.02M48.66M
% Held by Insiders i1.00%0.85%
% Held by Institutions i110.26%110.31%
% Held by Public i-11.26%-11.16%

Dividend Analysis & Yield Comparison: Veracyte Inc. vs Charles River Laboratories International, Inc.

MetricVCYTCRL
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A